Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Nov 20, 2024 · CIK: 1581178
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
Eupraxia Pharmaceuticals filed a 6-K on Nov 20, 2024, with a press release attached. Keep an eye out for updates.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 20, 2024, reporting on events for the month of November 2024. The filing includes Exhibit 99.1, which is a press release dated November 20, 2024. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing indicates ongoing reporting activity for Eupraxia Pharmaceuticals, which may contain updates relevant to investors regarding the company's operations or strategic developments.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant financial or operational disclosures that would immediately alter risk perception.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- November 20, 2024 (date) — Filing date and press release date
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (location) — Principal executive office address
- Bruce Cous (person) — Signatory for the filing
FAQ
What type of report is Eupraxia Pharmaceuticals Inc. filing?
Eupraxia Pharmaceuticals Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
What is the filing date of this Form 6-K?
The Form 6-K was filed as of November 20, 2024.
What documents are included as part of this report?
Exhibit 99.1, a Press Release dated November 20, 2024, is included as part of this report.
Where is Eupraxia Pharmaceuticals Inc.'s principal executive office located?
The company's principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Who signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
The Form 6-K was signed by Bruce Cous on behalf of Eupraxia Pharmaceuticals Inc.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-11-20 08:57:32
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 26KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001412.txt ( ) — 70KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: November 20, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer